The recent price drop in Hims & Hers Health (HIMS) is presented as a significant buying opportunity for long-term investors, as the stock is considered to be at its cheapest valuation level ever. The core thesis is that HIMS is a powerful marketing company disrupting healthcare, with its current legal issues being a temporary overreaction. For a different approach to the weight loss market, consider Eli Lilly (LLY) as the expected future leader. LLY is predicted to dominate the market by year-end 2026 due to its superior next-generation drug pipeline. While HIMS is a high-risk play on its current valuation, LLY is a bet on long-term market leadership.

Hims & Hers Health, Inc. (HIMS)

• The speaker is maintaining their long-term position in HIMS, choosing not to sell or add to their position amidst recent volatility. They view the stock as a "2030 and beyond story".
• Recent Price Action: The stock experienced a significant drop following news of a lawsuit and a poorly timed Super Bowl ad. It fell to $19.30 in after-hours trading on a Friday and was trading around $19.03 at the time of the podcast, which the speaker considers "holding up pretty well" after an initial panic-driven dip.
• Negative Catalysts Mentioned:
  • Analyst Downgrades: Analysts have lowered their price targets to as low as $12 and $15. The speaker dismisses this as analysts being "always late" and reacting to price movements rather than predicting them.
  • Novo Nordisk Lawsuit: Novo Nordisk (NVO) has filed a lawsuit against HIMS regarding the compounding of its patented GLP-1 drug, semaglutide.
  • Marketing Mistake: The speaker points to a "mistake" in a recent product launch where HIMS used the tagline "same ingredient as," which had previously drawn a warning from the FDA.
• Bullish Arguments / Long-Term Thesis:
  • Business Model Over Leadership: The speaker argues that the strength of the HIMS business model is more important than occasional leadership mistakes, drawing parallels to blunders made by leaders at Amazon (AMZN) and Microsoft (MSFT).
  • Limited GLP-1 Exposure: The speaker believes the market is overreacting to the lawsuit. They estimate that GLP-1 weight loss drugs represent "less than a third" of the company's business.
  • Pivot to Other Treatments: Even if HIMS loses the ability to sell compounded GLP-1s, they can pivot to other weight loss drugs like Metformin, which is in the public domain, and other customized oral pills.
  • Core Business Strength: The company was built on providing easy access to former blockbuster drugs like sildenafil (Viagra) and minoxidil (Rogaine), a business that remains strong.
  • "Marketing Machine": The core thesis is that HIMS is a superior marketing company with an excellent user interface (UI) and app experience, making healthcare accessible and desirable. This is contrasted with the clunky, user-unfriendly systems of traditional insurance and healthcare providers.
  • Valuation: The speaker claims that based on their valuation metric (a price-to-sales-to-growth ratio), the stock is at a 0.06, the "cheapest level the stock has ever been," comparable to when it traded at $5.

Takeaways

• The speaker presents a long-term bullish case for HIMS, suggesting that the current negative sentiment and price drop are a buying opportunity for those who believe in the long-term disruption of the healthcare industry.
• The lawsuit from Novo Nordisk is viewed as a major overhang, but the speaker sees a potential positive outcome: legal clarity on drug compounding. They also argue the financial impact may be limited as the GLP-1 market is expected to be dominated by Eli Lilly in the future.
• Investors should consider valuing HIMS on the strength of its core business and marketing platform, separate from the volatile and legally contentious GLP-1 segment.
• The stock is presented as a "roller coaster" and highly volatile. The speaker's strategy is to hold through the downturn, similar to how they held Tesla (TSLA) during its major drop to $130.

Eli Lilly (LLY)

• The speaker is very bullish on Eli Lilly's future in the weight loss market.
• They believe the market will "likely belong to Lilly towards year-end 2026" due to its superior product pipeline.
• Ritatrudide, an upcoming weight loss drug from Lilly, is highlighted as being "leaps and bounds ahead of semaglutide" (the drug from Novo Nordisk).
• The speaker predicts that once Ritatrudide is introduced, sales of current-generation GLP-1 drugs like semaglutide and tirzepatide will decline significantly.

Takeaways

• The podcast suggests a strong bullish outlook for Eli Lilly based on the expected dominance of its next-generation weight loss drugs.
• Investors interested in the massive GLP-1/weight loss market may want to look at LLY as a potential long-term leader, as it could capture significant market share from competitors like Novo Nordisk.

Novo Nordisk (NVO)

• Novo Nordisk is mentioned primarily in the context of its lawsuit against HIMS over the patent for its GLP-1 drug, semaglutide.
• The speaker believes NVO is taking a significant risk with the lawsuit, as it puts its own patent "to the test." A court could rule against the patentability of slightly modified, naturally occurring peptides like GLP-1s.
• The company faces a long-term competitive threat from Eli Lilly's superior drug pipeline, which could make its current blockbuster drugs less relevant by 2026.

Takeaways

• The lawsuit against HIMS creates a near-term headline risk for HIMS but also a long-term patent risk for Novo Nordisk.
• While a leader in the GLP-1 market today, the podcast implies that NVO faces significant future competition that could erode its market-leading position.